Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Single-Dose Two-Period Crossover Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Spinal Cord Injury
NCT01135108 is registered in ClinicalTrials.gov with KAI Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Randomized, Placebo-Controlled, Single-Dose Two-Period Crossover Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Spinal Cord Injury
- Lead sponsor
- KAI Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2009
- Completion date
- May 31, 2010
- Enrollment
- 5 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
spinal cord injury